CClinicalTrials.gg
RecruitingNCT07195240Updated Apr 13, 2026

The Effect of Lemongrass on Aerobic Performance

An interventional study of Active: Lemongrass and Control: Placebo in Sexual Wellness, Aerobic Capacity and Exercise Efficiency, sponsored by Northumbria University. Recruiting at 1 site in United Kingdom. Open to male participants aged 25 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Northumbria University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
Male
01

Study summary

The goal of this experimental study is to examine the influence of Lemongrass extract on aerobic training parameters following a 6-week training programme in males. A secondary aim will be to explore the influence on sexual wellness. Participants will attend 23 visits to the laboratory involving:

  • fitness testing (some to exhaustion).
  • blood sampling (capillary and venous samples).
  • a supervised 6 week high-intensity interval training (HIIT) programme.
  • consuming either the lemongrass extract or placebo in the form of tablets, once a day during the 6 week training.
Read the detailed description

The study is a randomised, parallel (two groups, lemongrass versus placebo), double-blind, placebo-controlled design in males (25-60 years).

Visit 1: Pre-screening Participants will receive information on the study, be assessed for contraindications, be familiarised with the requirements for participation, and provide written informed consent.

Visit 2: Familiarisation with the dependent measures Study staff will review physical activity questionnaires, and if eligibility criteria are met, participants will enter the trial. Participants will refrain from physical activity and alcohol consumption for 24 hours, and caffeine for 12 hours before each visit. Next, participants will be familiarised with the equipment to be used during the study.

Following a resting capillary blood lactate sample, participants will perform an exercise session on a cycle ergometer, beginning with a 5-minute warm-up at a self-paced intensity equating to approximately 10 on the 6-20 Rating of Perceived Exertion (RPE) scale.

The session will then start with the participant cycling at 50 watts (W) for 4 minutes, with an increase of 30 W every 4 minutes, while blood lactate is taken and heart rate recorded in the last 30 seconds of each stage. Once blood lactate has reached the second inflection point, the test will be terminated. Throughout the exercise session, expired air will be measured using online gas analysis.

Visit 3: Baseline measures Participants will report to the laboratory in a fed and hydrated state, having avoided strenuous activity for 24 hours, where baseline measurements of all dependent variables will be taken. Participants will complete a food diary for the 24-hour period prior to testing. The diary will be analysed using dietary analysis software, and participants will be instructed to replicate all food and fluid intake prior to the follow-up testing visit.

Upon arrival, a venous blood sample will be collected via the antecubital fossa, which will be frozen and stored for subsequent analysis of exercise-affected metabolites. Participants will then complete a sexual wellbeing questionnaire.

Following this, participants will repeat the submaximal protocol described in Visit 2. After a rest period of 10 minutes, participants will complete a graded exercise protocol to determine peak oxygen uptake (VO₂peak). The test will start at the intensity immediately below the second inflection point identified on the lactate profile. The intensity will increase by 30 W each minute until VO₂peak is achieved, which will be confirmed when at least one of the following criteria is met:

  • A plateau in VO₂ despite an increase in workload;
  • A respiratory exchange ratio (RER) higher than 1.15;
  • Peak heart rate at least equal to 90% of the age-predicted maximum;
  • RPE greater than 18;
  • Blood lactate concentration greater than 8 millimoles per litre (mmol·L-¹).

Maximum aerobic power will be defined as the final completed work rate. This will be used for subsequent training prescription (125% of maximal aerobic power [Pmax]).

Upon completion, participants will be supplied with their assigned product (lemongrass or placebo). They will consume one capsule daily, taken with the main meal prior to training sessions, with this timing repeated on non-training days.

6-Week Training Intervention (Visits 4-22) Participants will be required to attend three training sessions per week for a total duration of six weeks. Participants will complete a series of 30-second efforts at 125% of maximum Pmax (determined during the VO₂peak test), followed by 2 minutes of recovery.

In weeks 1-5, participants will complete 6, 7, 8, 9, and 10 intervals per session, respectively.

In week 6, participants will complete 8 intervals per session (to replicate a taper).

Each session will begin with a 5-minute, self-paced warm-up. Participants will maintain their habitual physical activity pattern between visits. Any exercise outside of the study will be recorded.

Visit 23: Post-training intervention testing Participants will repeat Visit 3 and complete all dependent measures within 48 hours of the final training session.

A follow-up communication via telephone will be conducted within 7 days of completion of the final session to ensure there are no adverse effects from participation.

02

Conditions studied

  • Sexual Wellness
  • Aerobic Capacity
  • Exercise Efficiency
03

In context

Lead sponsor

Northumbria University is the lead sponsor of 156 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age ≥ 40 and ≤ 60 years.
  • Body Mass Index (BMI) ≥ 19 and ≤ 35 kg/m2.
  • Willingness and ability to comply with the protocol in the opinion of the Investigator.
  • Judged by the Investigator to be in good health as assessed by a health screening questionnaire.
  • Currently identifies as the same biological sex as at birth.
  • Currently deemed to be between a physical activity status of sedentaryy to moderately trained (Meet World Health Organization minimum activity guidelines: Adults aged 18-64 years old completing at least 150 to 300 min moderate-intensity activity or 75-150 min of vigorous-intensity activity a week, plus muscle-strengthening activities 2 or more days a week).
  • Have a blood pressure \< 140/90 mmHg.

Exclusion criteria

Exclusion Criteria:

  • A history of heart disease.
  • Any disease that might interfere with the absorption of nutrients (e.g. Chron's disease, celiac disease).
  • Recent musculoskeletal or soft tissue injury (within the last 3 months).
  • The habitual use of medication that is antihypertensive or antidiabetic medication or might inhibit the ability to complete the study participation.
  • Alcohol Intake of greater than 21 units per week.
  • A change in bodyweight of more than 3kg within the month preceding the study.
  • Currently following a weight-loss or weight-gain programme.
  • Any known bleeding disorder or reaction to withdrawal of blood samples
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Active: Lemongrass Extract

    Tablet containing 200mg Lemongrass extract (Mibelle).

    Dietary Supplement: Active: Lemongrass

  • Experimental
    Control: Placebo

    Tablet containing microcrystalline cellulose.

    Dietary Supplement: Control: Placebo

Interventions

  • Dietary supplementActive: Lemongrass

    200mg of lemongrass extract

  • Dietary supplementControl: Placebo

    microcrystalline cellulose

06

What researchers measure

Primary outcomes

  1. Aerobic Capacity

    To determine the effect of the intervention vs placebo on marker of aerobic capacity (VO2peak). It will be assessed using breath-by-breath gas analysis during a graded exercise protocol on a static bike. The test will start at the intensity immediately below the second inflection point identified on the lactate profile (conducted in visit 2). The intensity will increase by 30 w each minute until VO2peak which will be confirmed when at least one of the following criteria (according to CASES) are met: (1) a plateau in VO2 despite an increase in workload; (2) a respiratory exchange ratio (RER) higher than 1.15; (3) peak heart rate at least equal to 90% of the age-predicted maximum and/or (4) RPE of \>18; (5) a blood lactate concentration of \> 8mMol/L. Maximum aerobic power will be defined as the final completed work rate. This will be used for subsequent training prescription (125% of maximal aerobic power \[Pmax\]).

    Time frame: This measure will assessed and measured twice: Baseline assessment: Visit 3 (Week 1, prior to the intervention). Post-intervention assessment: Visit 23 (Week 8, within 48 hours after the final training session).

  2. Aerobic Performance (blood lactate)

    To determine the effect of intervention vs placebo on secondary markers of maximal aerobic performance (blood lactate). A total of 14 (more if the submaximal exercise test progresses beyond 4 stages) capillary samples will be collected for each participant during the submaximal and graded exercise tests. This will be pre-exercise, then in the final minute of each ramped stage during the submaximal test. A final lactate sample will be collected upon completion of the VO2peak test. These samples will be analysed for lactate concentration immediately using a Biosen C-line analyser before being disposed of.

    Time frame: This measure will be assessed three times. Familiarisation and lactate profiling: Visit 2 (Week 0). Baseline assessment: Visit 3 (Week 1, prior to the intervention), Post-intervention assessment: Visit 23 (Week 8, within 48 hrs after the final training).

  3. Aerobic Performance (heart rate)

    To determine the effect, if any, of intervention vs placebo on secondary markers of maximal aerobic performance (heart rate). Heart rate will be continuously monitored using a chest strap (Polar monitor) throughout the various exercise protocols (lactate profiling in visit 2 and 3, and the graded exercise task in visit 3 and 23).

    Time frame: This measure will be assessed three times. Familiarisation and lactate profiling: Visit 2 (Week 0). Baseline assessment: Visit 3 (Week 1, prior to the intervention), Post-intervention assessment: Visit 23 (Week 8, within 48 hrs after the final training).

Secondary outcomes

  1. Sexual Wellness

    To determine, if any, changes in sexual wellbeing resulting from the intervention. Sexual wellbeing will be defined using a sexual function questionnaire (DISF-SR). Derogatis interview for sexual functioning-self report, set of 21 questions, split into four domains: sexual cognition/ fantasy, sexual arousal, sexual behaviour/ experiences and orgasm.

    Time frame: This measure will assessed and measured twice: Baseline assessment: Visit 3 (Week 1, prior to the intervention). Post-intervention assessment: Visit 23 (Week 8, within 48 hours after the final training session).

  2. Serum

    A total of 2 venous blood samples will be taken during visit 3 and visit 23, and serum will later be analysed for biomarkers associated with exercise metabolism to assess what effect, if any, the intervention has had on metabolites.

    Time frame: This measure will assessed and measured twice: Baseline assessment: Visit 3 (Week 1, prior to the intervention). Post-intervention assessment: Visit 23 (Week 8, within 48 hours after the final training session).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07195240
Lead sponsor
Northumbria University
Collaborators
Mibelle Group Biochemistry
Responsible party
Glyn Howatson (Professor, Northumbria University) — Principal investigator
First posted
Sep 26, 2025
Start date
Oct 24, 2025
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Emma Squires, Dr
Contact
emma2.squires@northumbria.ac.uk
07585775838
Glyn Howatson
principal investigator · Northumbria Univeristy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion